Close
Open Nav
Search Menu
Overview>Table>BIO Patient and Health Advocacy Summit: 2015 Schedule

Tuesday, October 6, 2015

12:30 PM - 1:30 PM: Keynote Luncheon:  Meaningful Patient Engagement in Drug Development

  • Opening Remarks: Paul J. Hastings, Chairman and CEO, OncoMed Pharmaceuticals
  • Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration (FDA)

1:45 PM - 3:00 PM:Patient Engagement 2.0: Advancing the Science of Patient Input

  • Moderator: Richard Pops, Chairman and CEO, Alkermes
  • Joel Beetsch, PhD, Vice President, Patient Advocacy, Celgene Corporation
  • Andrea Ferris, President and Chairman, LUNGevity Foundation
  • A. Brett Hauber, PhD, Senior Economist, Vice President of Health Preference Assessment, RTI International
  • Telba Irony, PhD, Chief, Biostatistics: General and Surgical Devices Branch, Center for Devices and Radiological Health, U.S. Food and Drug Administration 

3:15 PM - 4:30 PM: The Value of 21st Century Care: Defining and Building Value in Healthcare

  • Moderator: K. Kimberly McCleary, Managing Director, FasterCures
  • Linda House, President, Cancer Support Community
  • Fauzea Hussain, Vice President, Avalere Health
  • Rachel King, President and CEO, GlycoMimetics, Inc.
  • Cynthia Rice, Senior Vice President, Advocacy and Policy, JDRF

5:30 PM - 8:00 PM: Networking Reception at the Lincoln Restaurant

   Lincoln Restaurant
   1110 Vermont Avenue, NW
  Washington, DC, 20005

​Wednesday, October 7, 2015

8:00 AM - 9: 00 AM: Networking Breakfast at the Mayflower Hotel

   The Mayflower Hotel
  1127 Connecticut Avenue, NW
  Washington, DC 20036

9:00 AM - 10:15 AM: Best Practices for Industry and Patient Organization Collaboration in Clinical Trials

  • Moderator: Bray Patrick Lake, Director of Stakeholder Engagement, Clinical Trials Transformation Initiative
  • Paola Daly, Senior Manager of Health Outcomes Research, Lupus Foundation of America
  • David Leventhal, Director, Clinical Innovation, Worldwide Research and Development, Pfizer, Inc.
  • Michele Oshman, Director of Federal Advocacy Relations, Eli Lilly and Company
  • Wendy K.D. Selig, MSJ, Founder and CEO, WSCollaborative, LLC

10:30 AM - 11:45 AM: State and Regulatory Capacity Building Tracks

  • Track One: Partnerships to Improve Patient Access: State Advocacy Case Studies
    • Moderator: Patrick Plues, Senior Director, State Government Affairs, BIO
    • ​Amanda Chesley, JD, Executive Director, Coalition of State Rheumatology Organizations (CSRO) 
    • Mark Guimond, Director of State Legislative Affairs, Arthritis Foundation
    • Sharon Ladin, Executive Director, Advocacy, The Leukemia & Lymphoma Society
  • Track Two: Drug Development 101: How Drugs are Discovered, Developed, and Approved
    • Moderator: Fritz Bittenbender, Executive Vice President, Public Affairs, BIO
    • ​Steve Gibson, Chief Mission Strategy and Public Policy Officer, The ALS Association
    • Patrick Wildman, Vice President, Public Policy, The ALS Association
    • Steve Zelenkofske, Vice President, US-MA Cardiovascular, AstraZeneca

11:45 AM - 12:00 PM: Closing Remarks